DAPAGLIFLOZIN (dapagliflozin) by Aurobindo Pharma is sodium-glucose transporter 2 inhibitors [moa]. Approved for sodium-glucose cotransporter 2 inhibitor [epc]. First approved in 2026.
Drug data last refreshed 18h ago
Sodium-Glucose Transporter 2 Inhibitors
Sodium-Glucose Cotransporter 2 Inhibitor
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
OPTIMISE-CKD Study_Dapagliflozin Effectiveness in CKD
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin
dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation
A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.
Worked on DAPAGLIFLOZIN at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.